SCHEMBL5484358

SCHEMBL5484358

O=C(O)C(O)C(O)CCCO

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.44
TSHR P16473 2/20 0.43
CYP2C9 P11712 1/20 0.39
PGD P52209 1/20 0.39
OR51E2 Q9H255 1/20 0.36
CAMK2A Q9UQM7 1/20 0.36
PTPN1 P18031 2/20 0.35
GPR84 Q9NQS5 3/20 0.33
CHRM1 P11229 1/20 0.33
AKR1A1 P14550 1/20 0.33
CHRM3 P20309 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
ADRA1A P35348 1/20 0.33
HRH1 P35367 1/20 0.33
DRD3 P35462 1/20 0.33
SLC6A3 Q01959 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3299289 0.93 PDE4A (0.43) PDE4ATSHRCYP2C9PGDOR51E2
Succinic Acid SCHEMBL194222 0.91 CAMK2A (0.46) PDE4ATSHRCYP2C9PGDCAMK2A
SCHEMBL1110835 0.91 PDE4A (0.41) PDE4ATSHRCYP2C9PGDOR51E2
SCHEMBL6542236 0.91 PDE4A (0.41) PDE4ATSHRCYP2C9PGDOR51E2
SCHEMBL18322325 0.91 PDE4A (0.41) PDE4ATSHRCYP2C9PGDOR51E2
SCHEMBL9297279 0.91 PDE4A (0.41) PDE4ATSHRCYP2C9PGDOR51E2
SCHEMBL6686316 0.89 PDE4A (0.40) PDE4ATSHRCYP2C9PGDOR51E2
SCHEMBL2017250 0.86 PDE4A (0.52) PDE4ATSHRCYP2C9PGDOR51E2
SCHEMBL2784989 0.84 PDE4A (0.48) PDE4ATSHRCYP2C9PGDOR51E2
SCHEMBL28394802 0.80 FFAR1 (0.39) PDE4APTPN1FFAR1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020239083-A1 AEROSOL GENERATION OR SMOKING SYSTEM, OR ELECTRONIC CIGARETTE AND DEVICE THEREOF 钟术光 2020-12-03 WO claimed
CN-101538261-B Method for preparing (3R, 5S)-3, 5-O-isopropylidene-3, 5, 6-trihydroxy caproic acid hexylic acid derivative SICHUAN IND INST ANTIBIOTICS CHINA NAT PHARMACEUTICAL GROUP CORP 2012-11-07 CN claimed
CN-101538261-A Method for preparing (3R, 5S)-3, 5-O-isopropylidene-3, 5, 6-trihydroxy caproic acid hexylic acid derivative SICHUAN IND I OF ANTIBIOTICS C 2009-09-23 CN claimed
EP-0583171-B1 (3R,5S)-3,5,6-trihydroxyhexanoic acid derivatives and methods for their production TAKASAGO PERFUMERY CO LTD (JP) 1998-11-11 EP claimed
EP-0374922-B1 Process for the production of 3,5,6-trihydroxyhexanoic acid derivative KANEGAFUCHI CHEMICAL IND (JP) 1995-06-28 EP claimed
EP-0583171-A2 (3R,5S)-3,5,6-trihydroxyhexanoic acid derivatives and methods for their production Takasago International Corporation (JP) 1994-02-16 EP claimed
US-4983759-A Process for the production of 3,5,6-trihydroxyhexanoic acid derivative KANEGAFUCHI CHEMICAL INDUSTRY CO., LTD. (JP) 1991-01-08 US claimed
EP-0374922-A2 Process for the production of 3,5,6-trihydroxyhexanoic acid derivative Kanegafuchi Chemical Industry Co., Ltd. (JP) 1990-06-27 EP claimed
US-20250127925-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO HERCULES CAPITAL, INC. 2025-04-24 US disclosed
US-12076418-B2 Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo ENGENE, INC. (CA) 2024-09-03 US disclosed
US-20220133907-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO HERCULES CAPITAL, INC. 2022-05-05 US disclosed
EP-3970697-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO Engene, Inc. (CA) 2022-03-23 EP disclosed
US-11167045-B2 Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo HERCULES CAPITAL, INC. 2021-11-09 US disclosed
EP-3049473-B1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO ENGENE INC (CA) 2021-09-22 EP disclosed
EP-1288213-A1 PROCESS FOR PREPARING OPTICALLY ACTIVE 2- 6-(HYDROXY-METHYL)-1,3-DIOXAN-4-YL]ACETIC ACID DERIVATIVES KANEKA CORPORATION (JP) 2003-03-05 EP disclosed
EP-1288213-A1 PROCESS FOR PREPARING OPTICALLY ACTIVE 2- 6-(HYDROXY-METHYL)-1,3-DIOXAN-4-YL]ACETIC ACID DERIVATIVES KANEKA CORPORATION (JP) 2003-03-05 EP disclosed
WO-2001094337-A1 PROCESS FOR PREPARING OPTICALLY ACTIVE 2-[6-(HYDROXY-METHYL)-1,3-DIOXAN-4-YL]ACETIC ACID DERIVATIVES KANEKA CORPORATION (JP) 2001-12-13 WO disclosed
EP-0374922-B1 Process for the production of 3,5,6-trihydroxyhexanoic acid derivative KANEGAFUCHI CHEMICAL IND (JP) 1995-06-28 EP disclosed
US-4983759-A Process for the production of 3,5,6-trihydroxyhexanoic acid derivative KANEGAFUCHI CHEMICAL INDUSTRY CO., LTD. (JP) 1991-01-08 US disclosed
EP-0374922-A2 Process for the production of 3,5,6-trihydroxyhexanoic acid derivative Kanegafuchi Chemical Industry Co., Ltd. (JP) 1990-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250127925-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO CSGALNACT1, CHI3L2, LNPEP PDE4A 4587/4885TSHR 4331/4885CYP2C9 4006/4885
US-11167045-B2 Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo CSGALNACT1, CHI3L2, LNPEP PDE4A 4587/4885TSHR 4331/4885CYP2C9 4006/4885
US-12076418-B2 Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo CSGALNACT1, CHI3L2, LNPEP PDE4A 4587/4885TSHR 4331/4885CYP2C9 4006/4885
US-20220133907-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO CSGALNACT1, CHI3L2, LNPEP PDE4A 4587/4885TSHR 4331/4885CYP2C9 4006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.